For the quarter ending 2025-09-30, TNONW had -$4,404K decrease in cash & cash equivalents over the period. -$3,713K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Stock-based compensation expense | 58 | 1,289 |
| Depreciation and amortization | 77 | 90 |
| Amortization of operating right-of-use asset | 68 | 131 |
| Accounts receivable | 541 | -93 |
| Inventory | 484 | 70 |
| Prepaid expenses and other assets | -171 | 374 |
| Accounts payable | -259 | 525 |
| Accrued expenses | 499 | 142 |
| Operating lease liability | -74 | -138 |
| Net loss | -3,339 | -6,385 |
| Provision for credit losses on accounts receivable | 0 | 0 |
| Net cash used in operating activities | -3,824 | -4,697 |
| Purchase of assets from sivantage, inc | -750 | - |
| Purchases of property and equipment | -111 | 192 |
| Cash used in investing activities | -639 | -192 |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants | 4,010 | - |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants under inducement agreement | 0 | 3,057 |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants | - | 4,010 |
| Offering costs | -59 | 867 |
| Gross proceeds from issuance of series a convertible preferred stock | 0 | 0 |
| Gross proceeds from issuance of series b convertible preferred stock | 0 | - |
| Gross proceeds from issuance of common stock | 0 | 0 |
| Gross proceeds from issuance of common stock upon exercise of warrants | 0 | - |
| Net cash provided by financing activities | 59 | 6,200 |
| Effect of foreign currency translation on cash flow | 0 | 0 |
| Net (decrease) increase in cash and cash equivalents | -4,404 | 1,311 |
| Cash and cash equivalents at beginning of period | 6,535 | - |
| Cash and cash equivalents at end of period | 3,442 | - |
Tenon Medical, Inc. (TNONW)
Tenon Medical, Inc. (TNONW)